Literature DB >> 12414944

Addition of six-His-tagged peptide to the C terminus of adeno-associated virus VP3 does not affect viral tropism or production.

Huang-Ge Zhang1, Jinfu Xie, Igor Dmitriev, Elena Kashentseva, David T Curiel, Hui-Chen Hsu, John D Mountz.   

Abstract

Production of large quantities of recombinant adeno-associated virus (AAV) is difficult and not cost-effective. To overcome this problem, we have explored the feasibility of creating a recombinant AAV encoding a 6xHis tag on the VP3 capsid protein. We generated a plasmid vector containing a six-His (6xHis)-tagged AAV VP3. A second plasmid vector was generated that contained the full-length AAV capsid capable of producing VP1 and VP2, but not VP3 due to a mutation at position 2809 that encodes the start codon for VP3. These plasmids, necessary for production of AAV, were transfected into 293 cells to generate a 6xHis-tagged VP3mutant recombinant AAV. The 6xHis-tagged VP3 did not affect the formation of AAV virus, and the physical properties of the 6xHis-modified AAV were equivalent to those of wild-type particles. The 6xHis-tagged AAV did not affect the production titer of recombinant AAV and could be used to purify the recombinant AAV using an Ni-nitrilotriacetic acid column. Addition of the 6xHis tag did not alter the viral tropism compared to wild-type AAV. These observations demonstrate the feasibility of producing high-titer AAV containing a 6xHis-tagged AAV VP3 capsid protein and to utilize the 6xHis-tagged VP3 capsid to achieve high-affinity purification of this recombinant AAV.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12414944      PMCID: PMC136915          DOI: 10.1128/jvi.76.23.12023-12031.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Adeno-associated virus production of soluble tumor necrosis factor receptor neutralizes tumor necrosis factor alpha and reduces arthritis.

Authors:  H G Zhang; J Xie; P Yang; Y Wang; L Xu; D Liu; H C Hsu; T Zhou; C K Edwards; J D Mountz
Journal:  Hum Gene Ther       Date:  2000-11-20       Impact factor: 5.695

2.  An adeno-associated virus (AAV) initiator protein, Rep78, catalyzes the cleavage and ligation of single-stranded AAV ori DNA.

Authors:  R H Smith; R M Kotin
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Cation-exchange high-performance liquid chromatography of recombinant adeno-associated virus type 2.

Authors:  D Debelak; J Fisher; S Iuliano; D Sesholtz; D L Sloane; E M Atkinson
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-04-14

4.  Scaleable chromatographic purification process for recombinant adeno-associated virus (rAAV).

Authors:  C R O'Riordan; A L Lachapelle; K A Vincent; S C Wadsworth
Journal:  J Gene Med       Date:  2000 Nov-Dec       Impact factor: 4.565

5.  Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism.

Authors:  P Wu; W Xiao; T Conlon; J Hughes; M Agbandje-McKenna; T Ferkol; T Flotte; N Muzyczka
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  A method for the preparation of highly purified adeno-associated virus using affinity column chromatography, protease digestion and solvent extraction.

Authors:  R Anderson; I Macdonald; T Corbett; A Whiteway; H G Prentice
Journal:  J Virol Methods       Date:  2000-03       Impact factor: 2.014

7.  Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo.

Authors:  G Gao; G Qu; M S Burnham; J Huang; N Chirmule; B Joshi; Q C Yu; J A Marsh; C M Conceicao; J M Wilson
Journal:  Hum Gene Ther       Date:  2000-10-10       Impact factor: 5.695

8.  Chimeric virus-like particle formation of adeno-associated virus.

Authors:  M Hoque; N Shimizu; K i Ishizu; H Yajima; F Arisaka; K Suzuki; H Watanabe; H Handa
Journal:  Biochem Biophys Res Commun       Date:  1999-12-20       Impact factor: 3.575

9.  Genetic analysis of adeno-associated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function.

Authors:  J D Tratschin; I L Miller; B J Carter
Journal:  J Virol       Date:  1984-09       Impact factor: 5.103

Review 10.  Gene therapy: recombinant adeno-associated virus vectors.

Authors:  J R Smith-Arica; J S Bartlett
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 3.955

View more
  10 in total

1.  Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization.

Authors:  Michael A Lochrie; Gwen P Tatsuno; Brian Christie; Jennifer Wellman McDonnell; Shangzhen Zhou; Richard Surosky; Glenn F Pierce; Peter Colosi
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  Selection of novel vesicular stomatitis virus glycoprotein variants from a peptide insertion library for enhanced purification of retroviral and lentiviral vectors.

Authors:  Julie H Yu; David V Schaffer
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

Review 3.  AAV hybrid serotypes: improved vectors for gene delivery.

Authors:  Vivian W Choi; Douglas M McCarty; R Jude Samulski
Journal:  Curr Gene Ther       Date:  2005-06       Impact factor: 4.391

4.  AAV's anatomy: roadmap for optimizing vectors for translational success.

Authors:  Angela M Mitchell; Sarah C Nicolson; Jayme K Warischalk; R Jude Samulski
Journal:  Curr Gene Ther       Date:  2010-10       Impact factor: 4.391

5.  Immobilized cobalt affinity chromatography provides a novel, efficient method for herpes simplex virus type 1 gene vector purification.

Authors:  Canping Jiang; James B Wechuck; William F Goins; David M Krisky; Darren Wolfe; Mohammad M Ataai; Joseph C Glorioso
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

6.  Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus.

Authors:  Kenneth H Warrington; Oleg S Gorbatyuk; Jeffrey K Harrison; Shaun R Opie; Sergei Zolotukhin; Nicholas Muzyczka
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

7.  Targeted delivery system for cancer cells consist of multiple ligands conjugated genetically modified CCMV capsid on doxorubicin GNPs complex.

Authors:  Indu Barwal; Rajiv Kumar; Suneel Kateriya; Amit Kumar Dinda; Subhash Chandra Yadav
Journal:  Sci Rep       Date:  2016-11-22       Impact factor: 4.379

Review 8.  Scalable downstream strategies for purification of recombinant adeno- associated virus vectors in light of the properties.

Authors:  Weihong Qu; Mingxi Wang; Yaqing Wu; Ruian Xu
Journal:  Curr Pharm Biotechnol       Date:  2015       Impact factor: 2.837

9.  Adeno-associated virus capsid protein expression in Escherichia coli and chemically defined capsid assembly.

Authors:  Dinh To Le; Marco T Radukic; Kristian M Müller
Journal:  Sci Rep       Date:  2019-12-09       Impact factor: 4.379

10.  rAAV Engineering for Capsid-Protein Enzyme Insertions and Mosaicism Reveals Resilience to Mutational, Structural and Thermal Perturbations.

Authors:  Rebecca C Feiner; Julian Teschner; Kathrin E Teschner; Marco T Radukic; Tobias Baumann; Sven Hagen; Yvonne Hannappel; Niklas Biere; Dario Anselmetti; Katja M Arndt; Kristian M Müller
Journal:  Int J Mol Sci       Date:  2019-11-14       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.